tutorial on diabetes part 3 t5 — Transcript
Full transcript
- 0:03Okay, so now we have one last portion of
- 0:06the tutorial, which is the comparison of
- 0:08two drugs, the sulfonylureas
- 0:11and the biguanides.
- 0:13Just to precede the comparison though, I
- 0:16need to explain the fact that these two
- 0:19drugs are made for different types of
- 0:22diabetics.
- 0:24One of these drugs,
- 0:25the sulfonylureas,
- 0:27the way they primarily act is to
- 0:30increase insulin.
- 0:33And it would not be the kind of drug
- 0:36that you would, for instance, give to a
- 0:38woman with PCOS, polycystic ovarian
- 0:41syndrome or polycystic ovarian disease,
- 0:44uh or in, for instance, a person who has
- 0:46a problem controlling weight or even in
- 0:49the first stages of uh diabetes. The
- 0:53insulin is a part of that spiral of
- 0:55events that perpetuates, for instance,
- 0:58insulin insensitivity. It
- 1:01it perpetuates polycystic ovarian
- 1:04syndrome.
- 1:05So that is a medication
- 1:08that increases endogenous insulin and
- 1:12it's definitely not that first line
- 1:15therapy for people in early stages
- 1:18diabetes.
- 1:20But it is going to be helpful in, for
- 1:23instance, a later stage diabetes because
- 1:26in later stage diabetes, the pancreas of
- 1:29the client actually starts to put out
- 1:32less insulin.
- 1:34You you think about it. Uh
- 1:36a diabetic has been putting out a lot of
- 1:38insulin for a really long time
- 1:41and then eventually, very simplistically
- 1:44speaking, I mean it's not technically
- 1:45correct, but simplistically speaking,
- 1:48the pancreas burns out.
- 1:50Uh the other drug, metformin, increases
- 1:53insulin sensitivity.
- 1:56And it actually treats polycystic
- 1:59ovarian
- 2:01and it's very helpful in pretty much all
- 2:04stages of diabetes.
- 2:07So just get that picture in your mind
- 2:10that you're not just talking about two
- 2:13drugs that treat the exact same person.
- 2:17It's two drugs that treat the same
- 2:18disease, but they're very different
- 2:21drugs.
- 2:23And with that, we can begin to discuss
- 2:26the second sub question in this multi
- 2:28part tutorial question. And that is
- 2:31discuss gliclazide with respect to its
- 2:35suitability in the early stages of type
- 2:38two diabetes.
- 2:40And a note on that, you need to discuss
- 2:43gliclazide and not gliclazide modified
- 2:47release.
- 2:48So the normal gliclazide is the one
- 2:51you'll be discussing, and that's
- 2:53released immediately. So some of the
- 2:56newer articles out there will be
- 2:59discussing the modified released
- 3:02gliclazide. You will be discussing the
- 3:05normal gliclazide.
- 3:08And one of the first things that we need
- 3:10to know in order to understand
- 3:11gliclazide, or for that matter any of
- 3:13our drugs, is to understand its main
- 3:15mechanisms of action. Gliclazide is a
- 3:18sulfonylurea,
- 3:20and that drug class works by increasing
- 3:24the amount of insulin released from the
- 3:27pancreas.
- 3:29Now just knowing that, we can predict a
- 3:32number of things about that medication
- 3:34which are important to discuss in your
- 3:36answer to the question.
- 3:38The first is when the drug is
- 3:40appropriate in the progression of type
- 3:42two diabetes.
- 3:44In this graph,
- 3:46you see what normally happens in people
- 3:48who have pre diabetes, the first stages
- 3:51of diabetes, and the middle stages of
- 3:54diabetes. And as a matter of fact, in
- 3:56the latter stages of type two diabetes,
- 3:59the beta cell function, this line over
- 4:02here actually continues to decrease
- 4:05significantly to the point where there's
- 4:07often times little production of insulin
- 4:10in the long-standing diabetic, the type
- 4:13two diabetic.
- 4:15Notice this huge increase in insulin
- 4:18release in those early stages, the
- 4:20prediabetic stages. Indeed, as we have
- 4:23seen in this tutorial, that
- 4:25hyperinsulinemia
- 4:27during that time is responsible for
- 4:30quite a few of the manifestations.
- 4:32So let's just think about it.
- 4:35Would you predict that a medication that
- 4:37increases insulin release from the
- 4:39pancreas is going to be a preferred
- 4:42medication in the early stages of type
- 4:45two diabetes?
- 4:47No, the sulfonylureas are ideally placed
- 4:50in these latter stages of type two
- 4:52diabetes where the beta cells of the
- 4:55pancreas, simplistically put, start to
- 4:57fatigue.
- 4:59It's often times also used in the middle
- 5:01portion of diabetes where the normal
- 5:04production of insulin is kind of still
- 5:07maintained, but it's used in combination
- 5:10with, for instance, metformin that
- 5:12increases the sensitivity of the cells
- 5:14of the skeletal muscle and and so forth,
- 5:17those cells
- 5:18to use the endogenous insulin. So in
- 5:21that setting, the diabetic's glucose
- 5:24levels are not going to be maintained
- 5:26just by the one single drug.
- 5:29Knowing the action of that drug also
- 5:33allows us to predict some of the side
- 5:35effects of the drug as well.
- 5:37Gliclazide basically increases insulin
- 5:40release at the level of the pancreas.
- 5:42And remember what insulin does. This
- 5:45slide should refresh your memory on
- 5:46that. It increases
- 5:49fat synthesis, forcing adipocytes or fat
- 5:53cells to make triacylglycerols.
- 5:56It decreases lipolysis,
- 5:58and both of those actions
- 6:01of insulin will be resulting in an
- 6:04increase in weight gain.
- 6:07And then the high levels of insulin
- 6:09stimulate testosterone release from the
- 6:11female ovaries as well, contributing to
- 6:14the development and progression of
- 6:16polycystic ovarian syndrome.
- 6:20But what do you think the main side
- 6:22effect would be? The one that is
- 6:24actually life-threatening, maybe not as
- 6:26common as other ones, but the one that's
- 6:28really life-threatening.
- 6:30It would involve those increased levels
- 6:33of insulin, which is a hypoglycemic
- 6:37hormone.
- 6:38And what does, you know, what happens
- 6:40when we have high levels of a
- 6:42hypoglycemic
- 6:44hormone?
- 6:46What's the potential here?
- 6:48Yeah, yeah, hypoglycemia.
- 6:50Yes, there is an increase for every one
- 6:53of the sulfonylureas to develop
- 6:55hypoglycemia when you take that drug.
- 6:59That is the main number one side effect
- 7:01of all sulfonylureas. They all have a
- 7:04different kind of risk of developing
- 7:07hypoglycemia, and glipizide is one of
- 7:10the better ones. So it the likelihood of
- 7:14hypoglycemia isn't as high as, for
- 7:17instance,
- 7:18some of the other ones. But
- 7:21but it is still there, and therefore
- 7:24we're going to have to make sure to, you
- 7:26know, talk to the client about the risks
- 7:29of developing hypoglycemia.
- 7:32And just a note right here, when you
- 7:34hear that a number of drugs are termed
- 7:37oral hypoglycemic
- 7:39agents,
- 7:41you're going to kind of wonder why do
- 7:43they call it a hypoglycemic agent when
- 7:45it doesn't actually cause hypoglycemia?
- 7:48There are some
- 7:50hypoglycemic agents that don't cause a
- 7:53profound hypoglycemia, or sometimes they
- 7:56don't cause hypoglycemia at all.
- 7:57Sometimes they're they should be
- 7:59actually termed euglycemic. So they
- 8:02normalize the glucose levels.
- 8:05But the thing is that uh a lot authors
- 8:07use the term
- 8:09uh like hypoglycemic agent for even
- 8:11metformin, which has almost no
- 8:13possibility of causing hypoglycemia,
- 8:15just simply because it's an accepted
- 8:17term. It it just kind of means that it
- 8:20is actually decreasing the levels of the
- 8:24uh glucose to for instance a normal
- 8:27level or in some cases uh uh a subnormal
- 8:30level. So hypoglycemia in that instance.
- 8:34So just remember that the term oral
- 8:35hypoglycemic agent doesn't actually mean
- 8:38that it's going to definitely cause
- 8:39hypoglycemia and uh that it is used kind
- 8:43of uh just as a generic term to mean
- 8:47that it is going to decrease the level
- 8:48of glucose in the system.
- 8:52So back to glyburide,
- 8:54uh one of the important things that
- 8:55we're going to have to do when a client
- 8:57is prescribed a hypoglycemic agent that
- 9:00can cause hypoglycemia, so glyburide um
- 9:04is to inform them about what
- 9:06hypoglycemia is because they the client
- 9:08may not actually know. You know, we've
- 9:10got to tell them how serious it is.
- 9:12We've got to give them an idea of what's
- 9:14going to happen in the first stages of
- 9:16hypoglycemia so that they can actually
- 9:18identify it and you know what to do in
- 9:20the case of them experience experiencing
- 9:23a hypo.
- 9:25So you don't just tell them a hundred
- 9:27different signs. You don't just give
- 9:28them all of these signs that are on this
- 9:31page for instance. They would just it
- 9:32would just blur and they wouldn't
- 9:34actually remember any of it. So what you
- 9:36need to do is just give them a little
- 9:38bit of a picture and just say something
- 9:40to the effect of you know if you're
- 9:42experiencing a rapid extreme hunger and
- 9:45mental confusion, you may be about to
- 9:47experience a hypoglycemic attack or you
- 9:49may be in the middle of one. So what you
- 9:51need to do at that time is to drink
- 9:53something that has glucose in it and
- 9:56also you know give them a bit more
- 9:58education about hypoglycemia. So they
- 10:01need to eat or drink something that has
- 10:03some glucose in it, preferably glucose.
- 10:06Um yeah so uh uh we we always need to be
- 10:10safe. And client education is oftentimes
- 10:14a part of that safety.
- 10:17And another disadvantage in using
- 10:19gliclazide during the early stages of
- 10:21diabetes is it ultimately it contributes
- 10:25to early fatigue of the client's beta
- 10:28cells. So the pancreatic beta cells,
- 10:30remember back to this graph over here.
- 10:32Let's take a look at this one right
- 10:33here.
- 10:34So that insulin production
- 10:37is up in the early stages of diabetes.
- 10:39What what and and that right there that
- 10:42you know profound increase in the
- 10:44production of insulin from the beta
- 10:46cells of the pancreas, that actually
- 10:48leads to this dip over here in the later
- 10:52stages.
- 10:54So you know what would happen if for
- 10:56instance we gave an agent that increased
- 10:59this insulin even more? Well we would
- 11:01fatigue those beta cells even quicker.
- 11:04So ultimately
- 11:06uh the administration of gliclazide for
- 11:10instance is going to potentially
- 11:13uh fatigue lead to an earlier fatigue of
- 11:16the beta cells in and um yeah that's
- 11:19another one of those disadvantages
- 11:21you'll want to cite as far as the
- 11:23reasons that it wouldn't be an ideal
- 11:26medication for early diabetics.
- 11:30Because after we burn out basically burn
- 11:33out it's kind of a simplistic way of
- 11:35looking at it. Uh it's a bit more uh
- 11:38complicated technically. But uh as we
- 11:41burn out the beta cells um you know a
- 11:44person is going to have to start
- 11:45injections of insulin.
- 11:48And we oftentimes think of people who
- 11:51are injecting insulin as a type one
- 11:53diabetic where there's you know no
- 11:55functional beta cells at all. But in
- 11:58late stage diabetes type two there
- 12:00oftentimes is a need to inject insulin
- 12:02in those individuals. And they that's
- 12:05not to say that they have type one
- 12:07diabetes then. They still have type two
- 12:10diabetes but they just have fatigued
- 12:12beta cells with their disorder.
- 12:15So, what I'd like you to do right now is
- 12:17attempt this one in your own words, and
- 12:20just give a few pointers
- 12:23on your worksheet. And um we'll be
- 12:27coming back to you in just a little bit.
- 12:29So, discuss gliclazide with respect to
- 12:31its suitability in the early stages of
- 12:34type two diabetes. And just remember,
- 12:36the important thing is you discuss it.
- 12:40Why would it be good if it if there's
- 12:42any advantages? And why is it going to
- 12:44be bad?
- 12:45And um you know, so do the advantages
- 12:49outweigh the disadvantages and so forth?
- 12:51So, this is a discussion, and I'll just
- 12:53come back to you in just a little bit.
- 13:00So, on reflection of that question,
- 13:02almost all of the things you discuss
- 13:05will be negative aspects of using
- 13:07gliclazide because it simply isn't a
- 13:10first-line therapy for early stage
- 13:12diabetes. It's it's way down. It's not
- 13:15anywhere close to
- 13:17a recommended medication in early stages
- 13:20of diabetes.
- 13:21You might say something to the effect
- 13:22of, you know, while gliclazide may give
- 13:25some additional glucose-lowering effects
- 13:28in early stage diabetes, the dangers and
- 13:31side effects greatly outweigh the
- 13:34positive benefits that would be uh
- 13:37gained from using gliclazide. And as
- 13:41such, gliclazide is not recommended in
- 13:43the early stages of diabetes type two.
- 13:46And then you could mention the main
- 13:48mechanism of action being to stimulate
- 13:50the
- 13:51the pancreatic beta cells to release
- 13:53more insulin regardless of the current
- 13:55levels of glucose or of insulin itself,
- 13:59which is not ideal in prediabetes or
- 14:02early stage type two diabetes because
- 14:04the pancreas is already producing normal
- 14:07or even high amounts of insulin.
- 14:10But don't just stop there. What you need
- 14:12to do is say that, you know, since
- 14:15there's virtually no benefit in
- 14:17prescribing the drug during that time,
- 14:19the practical risks are very important
- 14:22to understand.
- 14:23And
- 14:24that's the point at which you mention
- 14:26the fact that it can cause
- 14:27life-threatening hypoglycemia and that
- 14:30there's an increase in insulin that will
- 14:33lead to weight gain. And that weight
- 14:36gain and the increase of insulin is
- 14:38going to predispose a female, for
- 14:40instance, to polycystic ovarian
- 14:43syndrome.
- 14:44And and it's also going to contribute to
- 14:47beta cell decline over time.
- 14:51So
- 14:52hopefully from that you have a picture
- 14:54of the sulfonylureas and where they fit
- 14:56into the progression of type two
- 14:58diabetes. It's definitely not a
- 15:01first-line therapy for early-stage
- 15:03diabetes.
- 15:05It's more of a later-stage treatment for
- 15:08diabetes when the beta cells are not
- 15:10really putting out enough insulin of
- 15:13their own.
- 15:14And the alternative to that during that
- 15:16time is that the person injects some
- 15:18insulin, some exogenous insulin.
- 15:22And are there any other questions on
- 15:24that?
- 15:26Okay, so everybody thinks that they have
- 15:28the type of answer that's going to score
- 15:30well in that question.
- 15:33Okay, and so if we don't have any
- 15:35questions, then the last diabetes drug
- 15:38that we're going to be discussing is the
- 15:39biguanide called metformin. Metformin is
- 15:43the first-line therapy for diabetes type
- 15:46two. It's the first-line therapy for,
- 15:48for instance,
- 15:50insulin resistance all the way to
- 15:53later-stage diabetes. And although diet
- 15:56and exercise is still the number one
- 15:59therapy for diabetes and for insulin
- 16:02resistance, metformin is our best
- 16:04medication for diabetes.
- 16:07And what I just said kind of addresses
- 16:09another question that you may have
- 16:11because
- 16:12there's about 50% of this tutorial
- 16:14dedicated to insulin resistance and, you
- 16:17know, how we would actually you know the
- 16:19risk factors of insulin resistance and
- 16:21so forth. And you know why is it that
- 16:24it's so disproportional you know why
- 16:25isn't it that we've actually spent more
- 16:27time on the drugs for diabetes. Well the
- 16:31main reason is because of the fact that
- 16:33the efficacy of diet and lifestyle
- 16:36therapies is far greater than metformin
- 16:39or metformin combined with anything
- 16:41else. So really your number one goal for
- 16:44diabetics is diet and exercise therapy
- 16:47and then of course we'd need to know our
- 16:49drugs as well.
- 16:50So this sub question relevant to
- 16:53metformin is discuss metformin with
- 16:56respect to the mechanisms of action and
- 16:58the most important side effects. So all
- 17:00we're asking for is the mechanisms of
- 17:02action and the most important side
- 17:04effects and remember in pharmacology the
- 17:07most important side effects pertain to
- 17:09the ones that are probably rare but can
- 17:13you know cause extreme harm or even
- 17:15death and the ones that are frequently
- 17:18seen and are often times the reason that
- 17:21the person cannot tolerate the drug. So
- 17:23those are the two
- 17:25you know groups of really important side
- 17:27effects when I ask you about important
- 17:29side effects.
- 17:30And with respect to the mechanisms of
- 17:32action there are quite a few minor
- 17:35mechanisms of action
- 17:37but we're just going to present the most
- 17:39important ones here. If you're shooting
- 17:41for a distinction or high distinction
- 17:42once again you'll have to supplement
- 17:44your answer with some well researched
- 17:47facts and also you'll have to reference
- 17:50those appropriately.
- 17:55And once again I have another hint for
- 17:57you. Make sure that you discuss the
- 17:58appropriate measures that will decrease
- 18:01the likelihood of the most important
- 18:04adverse effect.
- 18:07And just a further note on that hint
- 18:11metformin can rarely cause a thing
- 18:14called lactic acidosis. Um
- 18:17the the the biguanides were actually
- 18:20taken off the market because they
- 18:21severely they they caused lactic
- 18:24acidosis in a large percentage of
- 18:26people. But Metformin is still on the
- 18:28market
- 18:29and there is a rare chance of it causing
- 18:32lactic acidosis. That's a
- 18:33life-threatening disorder
- 18:35and of course
- 18:37once again you don't just list
- 18:40that as being a side effect.
- 18:43What are you going to do with that
- 18:44information? You know how are you going
- 18:46to make sure that that doesn't happen?
- 18:48In this instance it's really important
- 18:51that you take a look at the
- 18:55uh individual's liver function test
- 18:57because liver function test will give
- 18:59you a a bit of an idea of whether
- 19:01there's malfunction in the liver
- 19:04and make sure that they do have a good
- 19:06functioning liver and also make sure
- 19:08that they don't binge drink. So if you
- 19:10make sure of both of those things then
- 19:13there's almost no chance of Metformin
- 19:16causing lactic acidosis.
- 19:18So just in general I just want to make
- 19:20sure that you you don't just say
- 19:22Metformin can cause lactic acidosis. It
- 19:25would be more of a thing like
- 19:28because Metformin can cause lactic
- 19:31acidosis a liver function test
- 19:35should be performed and and you should
- 19:38make sure that they don't binge drink
- 19:40while taking the drug or something to
- 19:42that effect, okay? So not just
- 19:46it causes lactic acidosis.
- 19:49Okay, I'll discuss all of that in just a
- 19:52little bit but I just wanted to flag
- 19:55that in this little introduction to the
- 20:00uh the the question.
- 20:02Only specific biguanide that's available
- 20:05in Australia, New Zealand, and UK is
- 20:07Metformin.
- 20:09Metformin is a
- 20:11first-line therapy for diabetes
- 20:13mellitus. It's an oral hypoglycemic
- 20:17agent. Just a little history on that
- 20:20previous biguanides that were available
- 20:23included buformin and phenformin, but
- 20:26both of those were withdrawn from the
- 20:28market because they did have a very high
- 20:31risk of developing lactic acidosis.
- 20:35Metformin can cause lactic acidosis, but
- 20:38it's a very rare thing. And if we do our
- 20:41homework prior to
- 20:43having it prescribed, then the there's
- 20:46pretty much no chance of the person
- 20:47having lactic acidosis. So it's really
- 20:49important to do your homework with the
- 20:51individual client. First of all, let's
- 20:54back up and ask the question, you know,
- 20:55what is lactic acidosis?
- 20:58Lactic acidosis is a condition where
- 21:00there's an excess amount of lactate
- 21:03built up in the system.
- 21:05I made a simple flowchart so that you
- 21:07can see exactly what normally happens.
- 21:09So normally glucose
- 21:11is going to enter the cells. And we say
- 21:13that glucose is our energy supply, but
- 21:15the thing is that it's actually broken
- 21:17up into two pieces, two three-carbon
- 21:20moieties instead of one carbon one six
- 21:23carbon sugar. So so we break it up into
- 21:27two pyruvates
- 21:29and then the pyruvate is going to be our
- 21:31energy currency. And we get a lot of
- 21:33energy from the pyruvate. But there's
- 21:36always a little bit of this pyruvate
- 21:38that's not actually turned into energy
- 21:40straight away or there's not enough
- 21:42oxygen in the cell to turn it into
- 21:44energy. And what happens at that point
- 21:47is that the pyruvate turns into lactate,
- 21:50which is a bit acidic.
- 21:53The lactate is then kind of shipped
- 21:54around over to the liver and then the
- 21:57liver changes the lactate back to
- 22:00glucose. And then we can just use it
- 22:02with no problems.
- 22:04Well, this is where the buformins come
- 22:07unstuck because of the fact that one of
- 22:09the mechanisms of action of metformin is
- 22:12that it decreases the hepatic production
- 22:15of glucose.
- 22:17And one of the very ways that it does
- 22:19that is that it affects the liver's
- 22:21ability to change lactate back into
- 22:24glucose.
- 22:26With a good functioning liver, it's
- 22:29still no problem, but uh if the person
- 22:32does have liver disease or if they binge
- 22:35drink, that person could wind up with
- 22:37lactic acidosis, which is that increased
- 22:41systemic amount of uh lactate uh of the
- 22:44acidic lactate.
- 22:46And I did say, you know, if the person
- 22:48binge drinks, you know, what what does
- 22:49binge drinking have to do with it? Well,
- 22:52anytime a person binge drinks, they're
- 22:53basically
- 22:55giving themselves a temporary liver
- 22:57malfunction because the liver says, wow,
- 23:00uh I'm going to have to deal with this
- 23:02straight away. So the so so the liver
- 23:04actually metabolizes the alcohol
- 23:06straight away, puts everything else on
- 23:07hold, and basically you can kind of
- 23:10regard the liver being a bit of a
- 23:12malfunctioning state at that point.
- 23:16So before a person is prescribed
- 23:18metformin, the client should be checked
- 23:20to make sure that they number one don't
- 23:22have any liver problems, number two they
- 23:24don't binge drink, and number three that
- 23:27they have a good functioning set of
- 23:29kidneys. So the kidneys are are really
- 23:32important in this lactate as well.
- 23:35The uh liver function test gives you the
- 23:38information about the liver. So as the
- 23:40enzymes are high, it means that there's
- 23:43damage in the liver and you need to look
- 23:45into it.
- 23:46Uh
- 23:47the the blood urea nitrogen and also the
- 23:50creatinine
- 23:52is the thing that gives you the
- 23:54information about the function of the
- 23:56kidneys, and you'll just need to make
- 23:59sure to ask the person how much alcohol
- 24:01they consume as well.
- 24:03The other mechanism by which metformin
- 24:06works is this one right here by
- 24:08increasing the insulin sensitivity. So
- 24:11metformin actually increases the binding
- 24:14of insulin to the receptor, makes it
- 24:16stick there longer, and therefore we
- 24:18have more glucose port transport carrier
- 24:21molecules. So you remember all the
- 24:23things that I was saying about
- 24:25hyperinsulinemia
- 24:28and the things that hyperinsulinemia can
- 24:31cause, well,
- 24:33would you think that this drug would
- 24:35actually be good for the people who have
- 24:38obesity and polycystic ovarian syndrome?
- 24:41It is. Yes. So this is the this is where
- 24:44you would actually choose Okay, you've
- 24:46got two patients over here. Uh one
- 24:48patient is uh moderately obese. She's 24
- 24:52years of age. Uh she's had a little bit
- 24:54of problems menstruating and and that
- 24:56kind of thing. And well, you choose
- 24:59metformin for this person. You you don't
- 25:01choose the sulfonylureas for this person
- 25:05because the fact that um you know, the
- 25:07metformin actually has a a potential of
- 25:10normalizing some of that
- 25:12uh cascade of events that's occurring in
- 25:15her polycystic ovarian syndrome.
- 25:18Whereas the sulfonylureas are going to
- 25:20do the exact opposite. They're actually
- 25:22going to make that worse. Conversely, if
- 25:24you had another patient who is has been
- 25:27a diabetic for a really long period of
- 25:29time, often times their problem is that
- 25:31they're actually decreasing the amount
- 25:34of insulin in their production. They
- 25:37can't make enough insulin normally.
- 25:40Their stimulus for making that insulin
- 25:43isn't enough. And that's where your
- 25:45sulfonylureas would come in.
- 25:47So that is a really important
- 25:51mechanism of action, this one for
- 25:52metformin, and that's the reason that
- 25:54metformin is the number one therapy for
- 25:57diabetics.
- 25:58And then you may mention that there is
- 26:01also a decrease absorption of glucose
- 26:04from the gastrointestinal tract. So this
- 26:07is a representation of a uh microvilli
- 26:12and the glucose coming into the body.
- 26:15We do have a little bit of a decrease
- 26:17absorption of that which just adds a
- 26:19little bit extra support with metformin.
- 26:22I guess the other time that you might
- 26:24use the sulfonylureas
- 26:27would be
- 26:28with perhaps like let metformin when
- 26:31they're really really have a super high
- 26:34level of glucose and they're really
- 26:37damaging their neurons, they're really
- 26:39damaging their retina of the eye, their
- 26:41glomerulus with this high level of
- 26:44glucose because the higher level of
- 26:46glucose we get the worse it is for all
- 26:49of those delicate structures in the
- 26:51body. So there's a few applications for
- 26:54the sulfonylureas, but it's definitely
- 26:56not in that patient who has potentially
- 27:00polycystic ovarian syndrome developing.
- 27:03This just gets to a couple questions and
- 27:05how does it affect the weight? And
- 27:08metformin doesn't really have any effect
- 27:10on the weight in type 2 diabetes
- 27:12patients, but if anything it's actually
- 27:15going to decrease the weight.
- 27:17And so when you do when you take a
- 27:20double-blind placebo-controlled trial of
- 27:22a cohort of individuals and you're
- 27:23saying does it do this or this, there's
- 27:25certain individuals who will respond
- 27:28well and actually get some benefit and
- 27:30actually get some weight reduction, but
- 27:33as you average everything out their
- 27:36weight is not affected. Metformin has
- 27:38been used off-label though as a weight
- 27:41loss agent. So
- 27:43if the person doesn't have diabetes or
- 27:45has prediabetes sometimes they give it
- 27:48kind of like as an off-label medication
- 27:51for decreasing the weight and
- 27:53normalizing things.
- 27:56Other things can it cause hypoglycemia?
- 27:58I would say it almost never happens
- 28:01and nobody in medicine really says never
- 28:05never ever ever never happens because
- 28:07there's always an exception to the rule.
- 28:09You know you you really don't have to
- 28:11worry about hypoglycemia with metformin
- 28:13if it's a monotherapy. Obviously if
- 28:16you're combining it with the
- 28:18sulfonylureas
- 28:19then that's the point at which you need
- 28:21to think about the possibility of
- 28:23hypoglycemia forming.
- 28:25And it's also been used to prevent
- 28:28diabetes as well. So just at that stage
- 28:31of insulin insensitivity to try to get
- 28:34the muscles cells to become sensitive to
- 28:38the insulin. If you get them to become
- 28:40sensitive to the insulin, then you
- 28:44often times delay the onset of actual
- 28:46diabetes.
- 28:48But the other thing is that how does
- 28:50this compare to diet and exercise? Diet
- 28:52and exercise therapy is actually more
- 28:55efficacious. So if you do have the
- 28:58opportunity to work with the patient
- 29:00with the diet and exercise therapy and
- 29:02there's a lot of diet and exercise
- 29:03therapies that would be beneficial for
- 29:06this patient, but
- 29:08but
- 29:09biguanides are only about half as
- 29:11effective as the diet and and as a
- 29:13really good diet and exercise therapy.
- 29:17This is just flow chart of the
- 29:20relationship between weight and
- 29:22polycystic ovarian syndrome and just
- 29:25placing some of the things in this flow
- 29:29chart. So the obesity occurs in like you
- 29:32never know where does it happen. It's
- 29:34kind of like the chicken or the egg kind
- 29:36of scenario where it's a a vicious cycle
- 29:40and somebody gets insulin resistance.
- 29:42That might be the first thing and then
- 29:44the insulin resistance actually does
- 29:46contribute to the obesity as we were
- 29:48saying before because it actually
- 29:50increases levels of insulin and the
- 29:52increased levels of insulin increase
- 29:54obesity. So the obesity then goes and
- 29:57and increases the insulin resistance and
- 30:01then hyperinsulinemia and and and that
- 30:04starts changing the production of
- 30:06hormones at the level of the ovaries
- 30:08winds up with polycystic ovarian
- 30:09syndrome and this and the thing goes
- 30:11around and around in circles.
- 30:13So where does metformin work? Well, we
- 30:16have a decrease in insulin resistance.
- 30:19So we have this this is the
- 30:21one of the main portions of the cycle
- 30:24that metformin is going to work. But
- 30:27like I said with all chronic disorders,
- 30:29you don't want to just do one thing. If
- 30:31you can get something else in there, if
- 30:33you can actually, you know, get them to
- 30:35decrease their weight as well as as
- 30:38giving them a
- 31:44symptoms will be alleviated or decreased
- 31:48quite substantially.
About this transcript
This page contains the full transcript of tutorial on diabetes part 3 t5 by PharmacoPhoto, generated from the public captions YouTube serves with the video. The transcript has 4,469 words across 744 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.